Wave Life Sciences, Inc. (NASDAQ:WVE)
| Market Cap | $504.91M-63.7% |
| Revenue (ttm) | $70.92M-35.1% |
| Net Income | -$210.53M-72.6% |
| EPS | -$1.07-42.7% |
| Shares Out | 197.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,279,709 |
| Open | $2.65 |
| Previous Close | $2.72 |
| Day's Range | $2.54 - $2.79 |
| 52-Week Range | $2.54 - $21.73 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $11.75(+358.98%) |
| Earnings Date | Feb 25, 2027 |
About WVE
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
5 firms rating WVE in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$WVE stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in WVE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by WVE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
WVE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New WVE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to WVE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in WVE
| IWMiShares Russell 2000 ETF | $9.87M |
| VXFVanguard Extended Market ETF | $6.21M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $5.45M |
| IBBiShares Biotechnology ETF | $3.43M |
| IWNiShares Russell 2000 Value ETF | $3.38M |
| VTWOVanguard Russell 2000 ETF | $2.98M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from WVE’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.17% |
| WDNA | WisdomTree BioRevolution Fund | 0.97% |
| SPIT | F/m Emerald Special Situations ETF | 0.97% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.43% |
| LFSC | F/M Emerald Life Sciences Innovation ETF | 0.42% |
| GNOM | Global X - Genomics & Biotechnology ETF | 0.41% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.41% |
| OZEM | Roundhill Investments - GLP-1 & Weight Loss ETF | 0.24% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.18% |
| IWC | iShares Micro-Cap ETF | 0.12% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.10% |
| KOMP | State Street SPDR S&P Kensho New Economies Composite ETF | 0.05% |
Weight is the stock’s share of each fund’s holdings.
